Ready, Set, Go: ‘Unprecedented’ FDA Guidance Aims To Unburden Coronavirus Test Makers, Speed Process
The US agency issued a guidance document that significantly lowers regulation of diagnostics used specifically to fight the ongoing COVID-19 pandemic. The new policies give states far more autonomy, allow diagnostics makers to distribute products before an Emergency Use Authorization is issued by the FDA, and permits certain serological tests on the market if they adhere to proper labeling.
You may also be interested in...
The Texas company is planning to sell 30,000 at-home sample collection kits for COVID-19 testing beginning on 23 March.
Medtech Insight is tracking the IVD companies manufacturing tests for SARS-CoV-2, the coronavirus that causes COVID-19.
The US agency issued a revised version of an Emergency Use Authorization (EUA) to the Centers for Disease Control and Prevention for the CDC’s COVID-19 test on 15 March, and approved an amendment to New York State’s EUA for its assay on the same day.